Lawsuits against Invokana have been filed since the drug hit market in 2013. Invokana can cause serious complications – like bone fractures and diabetic ketoacidosis – which could lead to hospitalization and lifelong health concerns.
Why File an Invokana Lawsuit?
Since its FDA approval in March 2013, Invokana has reached roughly $1 billion in annual sales. The drug was produced as an alternative solution for people with type 2 diabetes. Rather than altering insulin levels, Invokana lowers blood sugar levels by working with the kidneys to remove excess sugar through the urine.
Despite only being on the market for a short period of time, Invokana has been the subject of thousands of lawsuits. Invokana lawsuits claim the manufacturer of the drug failed to warn consumers about potentially life-threatening side effects.
Some of the severe complications consumers on Invokana have experienced include:
- Kidney failure
- Heart issues
- Bone fractures
- Decrease in bone mineral density
Following FDA safety communication messages about Invokana, a surge of lawsuits were filed claiming the manufacturer knew about the damaging risks and downplayed them to consumers. The allegations also say that Janssen Pharmaceuticals should be held accountable for the severe complications thousands of individuals have experienced.
If you have experienced any harmful side effects from taking Invokana, you may be entitled to compensation for pain and suffering, lost wages and medical bills.
Who is Responsible for Invokana Complications?
Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, manufactures and distributes Invokana. From its initial distribution, there has been much debate about the drug’s warning label. For example, its first warning label lacked information about cardiovascular complications that had been discovered during clinical trials. After similar issues were reported, the FDA revised Invokana’s labeling.
Numerous lawsuits allege that serious side effects could have been avoided. Individuals have voiced concerns that the manufacturer possibly knew about the adverse effects, yet still put consumers at risk.
Additionally, some people have said that they continue to suffer severe and irreversible injuries after taking Invokana. Oftentimes, these conditions may require ongoing medical care and attention.
Legal Complaints Against Invokana
A large number of individuals have filed lawsuits against Invokana for varying reasons; however, many are related to deceptive marketing.
Complaints about Invokana often cite:
- Failure to warn patients of harmful risks
- Distortion of marketed risks and benefits
- Production and manufacture of a defective drug
The most common issues relate to lack of information about diabetic ketoacidosis (DKA), which can sometimes turn into a life-threatening health condition.
Invokana Ketoacidosis (DKA)
Many people are holding Janssen Pharmaceuticals responsible for failing to disclose the risk of ketoacidosis – also known as diabetic ketoacidosis – that has been linked to Invokana. With DKA, the body produces abnormally high levels of acid in the blood. This condition can require hospitalization.
Warning signs of DKA may go unnoticed if they develop quickly. According to Mayo Clinic, DKA symptoms may include:
- Excessive thirst
- Frequent urination
- Nausea and vomiting
- Abdominal pain
- Weakness of fatigue
- Shortness of breath
Other factors that may trigger DKA include a heart attack, surgery, stress, alcohol or drug abuse, and emotional or physical trauma. DKA can lead to a diabetic coma or even death if left untreated.
In 2015, the FDA issued a safety communication regarding SGLT2 inhibitors, like Invokana, on the basis that the drugs may lead to DKA.
Most recently, the FDA issued a safety communication message about an increased risk of foot and toe amputations from Invokana. The organization is currently investigating this issue.
Another FDA safety review in 2015 required more warnings on Invokana labels as to the risk of too much acid in the blood and serious urinary tract infections.
The first warning looked into reports from individuals who experienced DKA as a result of taking Invokana. The FDA stated that in many of the cases, it was not immediately recognized because the individual’s blood sugar levels were below those generally expected for DKA. As a result, treatment was delayed in some cases, potentially leading to more serious complications.
Additionally, the FDA identified severe cases of blood infections and kidney infections that started as urinary tract infections. In several situations, patients needed to be hospitalized to start immediate treatment of kidney failure.
Proceeding with an MDL is typically the most efficient and effective way of handling claims against pharmaceutical manufacturers of products like Invokana.With the number of lawsuits coming forward against Janssen Pharmaceuticals, cases may be consolidated as a multidistrict litigation (MDL) in federal court.
Getting an Attorney who knows Invokana
Janssen Pharmaceuticals potentially withheld crucial information and failed to warn consumers about the harmful side effects linked to Invokana. A growing number of lawsuits continue to be filed in order to hold them accountable for misleading the public about the drug and its risks.
It’s important to work with an attorney who has vast experience in working with MDL pharmaceutical cases. Our legal experts will evaluate your case and provide you with the best option to receive financial compensation.
Last Edited: October 31, 2017
- U.S. Food and Drug Administration. (2016). FDA. July 2016. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm501565.htm
- Brian Beltz. (2015). The ‘Cure’ to Type 2 Diabetes. July 2016. http://www.huffingtonpost.com/brian-beltz/the-cure-to-type-2-diabet_b_8252442.html
- Miriam E. Tucker. (2015). Warning: SGLT-2s Can Cause DKA at Near-Normal Glucose Levels. July 2016. http://www.diabetesforecast.org/2015/sep-oct/warning-sglt-2s-can-cause.html
- U.S. Food and Drug Administration. (2016). FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. July 2016. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm
- U.S. Food and Drug Administration. (2016). Interim clinical trial results find increased risk of leg and foot amputations, mostly affecting the toes, with the diabetes medicine canagliflozin (Invokana, Invokamet). July 2016. http://www.fda.gov/Drugs/DrugSafety/ucm500965.htm